NervGen Pharma Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Adam H. Rogers
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2955 Virtual Way Vancouver BC Canada V5M 4X6
- IPO Date
- Apr 3, 2019
- Website
- nervgen.com
- Similar Companies
- Business
- NervGen Pharma Corp. (TSX-V: NGEN, OTCQB: NGENF), a clinical-stage biotechnology company founded in 2017 and headquartered in Vancouver, Canada, discovers, develops and commercializes innovative peptide-based therapeutics to promote nervous system repair following neurotrauma and degenerative neurologic diseases; its lead product candidate, NVG-291, a first-in-class subcutaneously administered peptide that targets chondroitin sulfate proteoglycan (CSPG) inhibitory molecules to enable nervous system plasticity and repair, advances in a Phase 1b/2a proof-of-concept clinical trial for spinal cord injury (SCI) with positive topline results from the chronic cohort (1-10 years post-injury) announced in June 2025 demonstrating nervous system repair, alongside preclinical evaluations in stroke, multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, blast-induced sensorineural hearing loss and peripheral nerve injury supported by recent U.S. Department of Defense-sponsored studies; the company advances NVG-300, a novel discovery-stage candidate in preclinical models of ischemic stroke and confirmatory SCI. NervGen operates primarily in North America with global clinical trial recruitment and maintains a licensing agreement with Case Western Reserve University for patented peptide technology targeting nerve damage conditions. Recent developments include the July 2025 appointment of Chairman Dr. Adam Rogers as Interim CEO to drive strategic growth following positive SCI trial data, completion of a US$10 million non-brokered private placement financing in November 2025 led by Sci Ventures, PFP Biosciences Holdings and The Paul and Phyllis Fireman Charitable Foundation to support anticipated Nasdaq listing and NVG-291 advancement including planned FDA end-of-Phase II meeting in early 2026, positive preclinical data releases in August 2025 and ongoing Phase 1b/2a subacute SCI cohort trial progression.
NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury
NervGen Pharma Begins Trading on Nasdaq Today
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS
NervGen Pharma Announces Proposed Amendment to Warrants
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury
NervGen Announces Leadership Transition to Support Strategic Growth and Expansion
NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update
NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth
NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones
NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
NervGen Pharma: Risky, Yet Promising With Big Upside
NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting
NervGen Pharma Grants Stock Options
NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates